Christopher J. Swearingen

Christopher J. Swearingen

Auto-generated profile, based on publicly available information

Christopher J. Swearingen

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1999 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
TPTheodore Pincus
Theodore Pincus
CSChristopher Swearingen
Christopher Swearingen
FWFrederick Wolfe
Frederick Wolfe
Objective To develop components of a multidimensional Health Assessment Questionnaire (MDHAQ) through the addition of new items in the “patient‐friendly” HAQ format, including advanced activities of daily living (ADL), designed to overcome “floor effects” of the HAQ and modified HAQ (MHAQ) in which patients may report normal scores although they experience meaningful functional limitations, and psychological items, designed to screen efficiently for psychological distress in routine care. Methods The new MDHAQ items, as well as scales for pain, fatigue, helplessness, and global health status on a 2‐page questionnaire, were completed by 688 consecutive patients with various rheumatic diseases, including 162 with rheumatoid arthritis (RA), 114 with fibromyalgia, 63 with osteoarthritis, 34 with systemic lupus erythematosus, 20 with vasculitis, 18 with psoriatic arthritis, 16 with scleroderma, and 261 with various other rheumatic diseases, over 2 years at a weekly academic rheumatology clinic. Results The new MDHAQ items have good test–retest reliability and face validity. MHAQ scores were highest in patients with RA, and scores for other scales were highest in patients with fibromyalgia. On the advanced ADL, 58% of patients reported difficulty with errands, 68% with climbing stairs, 79% with walking two miles, 87% with participating in sports and games, and 94% with running or jogging two miles. On the psychological items, 75% of patients reported difficulty with sleep, 63% with stress, 61% with anxiety, and 57% with depression. Normal MHAQ scores were reported by 23% of patients and normal HAQ scores by 16% of patients who completed these questionnaires, while fewer than 5% had normal scores on the MDHAQ. Conclusion The MDHAQ items overcome in large part the “floor effects” seen on the HAQ and MHAQ, and are useful to screen for problems with sleep, stress, anxiety, and depression in the “patient‐friendly” HAQ format. These data support the value of completion of a simple 2‐page patient questionnaire by each patient at each visit to a rheumatologist.

1 November 2008 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
TPTheodore Pincus
Theodore Pincus
CSChristopher J. Swearingen
Christopher J. Swearingen
MBMartin Bergman
Martin Bergman
YYYusuf Yazici
Yusuf Yazici
Objective: To compare 4 categories (high, moderate, and low severity, and near-remission) of RAPID3 (Routine Assessment of Patient Index Data 3), an index without formal joint counts, which is scored in < 10 seconds to 4 categories of the DiseaseActivity Score (DAS28) and Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA).Methods: All patients complete a Multidimensional Health Assessment Questionnaire (MDHAQ) at each visit. A physician/assessor 28-joint count and erythrocyte sedimentation rate (ESR) were completed in 285 patients with RA in usual care by 3 rheumatologists to score DAS28, CDAI, and RAPID3. RAPID3 includes the 3 MDHAQ patient self-report RA Core Data Set measures for physical function, pain, and patient global estimate. Proposed RAPID3 (range 0–10) severity categories of high (> 4), moderate (2.01–4), low (1.01–2), and near-remission (≤ 1) were compared to DAS (0–10) activity categories of high (> 5.1), moderate (3.21–5.1), low (2.61–3.2), and remission (≤ 2.6), and CDAI (0–76) categories of > 22, 10.1–22.0, 2.9–10.0, and ≤ 2.8. Additional RAPID scores, which add to RAPID3 a physician/assessor or patient self-report joint count and/or assessor global estimate, were also analyzed. Statistical significance was analyzed using Spearman correlations, cross-tabulations, and kappa statistics.Results: All RAPID scores were correlated significantly with DAS28 and CDAI (rho > 0.65, p < 0.001). Overall, 78%–84% of patients who met DAS28 or CDAI moderate/high activity criteria met similar RAPID severity criteria, and 68%–77% who met DAS28 or CDAI remission/low activity criteria also met similar RAPID criteria. RAPID3 was as informative as other indices.Conclusion: RAPID3 provides a feasible, informative quantitative index for busy clinical settings.

1 February 2005 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
YYY Yazici
Y Yazici
TST Sokka
T Sokka
HKH Kautiainen
H Kautiainen
CSC Swearingen
C Swearingen
IKI Kulman
I Kulman
TPT Pincus
T Pincus
Objective: To analyse patients with rheumatoid arthritis, treated with methotrexate in a weekly academic rheumatology clinic over 13 years, for continuation of courses and reasons for discontinuation. Methods: All 248 patients with an analysable longitudinal course who took methotrexate in standard care between 1990 and 2003 were studied. Continuation of courses was analysed using life tables. All abnormal and severely abnormal values for aspartate aminotransferase (AST) >40 U/l, >80 U/l, albumin <35 g/l, <30 g/l, white blood cell (WBC) count <4.0×109/l, <3.0×109/l, and platelet count <150×109/l, 80 U/l, 1.1 for albumin <30 g/l, 0.7 for WBC <3.0×109/l, and 0.3 for platelets <100×109/l. No severe laboratory abnormality progressed to further severity or clinical disease. Permanent discontinuations of methotrexate occurred in 46 patients (19%), 26 (10% of all patients) for adverse effects, 15 (32.6%) for inefficacy; only two discontinuations resulted from laboratory abnormalities, both of WBC, possibly from other sources. Conclusions: Methotrexate was associated with a high rate of continuation, and few clinically significant laboratory abnormalities. Discontinuation primarily reflected clinical rather than laboratory findings. Vigilance for methotrexate toxicity is required but methotrexate appears among the safest treatments for rheumatoid arthritis.

28 January 2010 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
TPTheodore Pincus
Theodore Pincus
CSChristopher J. Swearingen
Christopher J. Swearingen
MBMartin J. Bergman
Martin J. Bergman
CCC. Lee Colglazier
C. Lee Colglazier
AKAlan T. Kaell
Alan T. Kaell
YYYusuf Yazici
Yusuf Yazici

23 June 2011 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
RHRennie G. Howard
Rennie G. Howard
MPMichael H. Pillinger
Michael H. Pillinger
SGSoterios Gyftopoulos
Soterios Gyftopoulos
RTRalf G. Thiele
Ralf G. Thiele
CSChristopher J. Swearingen
Christopher J. Swearingen
JSJonathan Samuels
Jonathan Samuels
Objective: Criteria for sonographic diagnosis of monosodium urate (MSU) crystal deposition have been developed, but the interreader reproducibility of this modality is not well established. We therefore assessed agreement using a systematic approach.Methods: Fifty male subjects ages 55–85 years were recruited during primary care visits to an urban Veterans Affairs hospital, and were assessed by musculoskeletal ultrasound (US) of the knees and first metatarsophalangeal (MTP) joints to evaluate for the double contour sign and tophi as evidence of MSU crystal deposition. Images were read by 2 blinded rheumatologists trained in musculoskeletal US, and the degree of concordance was determined for individual subjects, total joints, femoral articular cartilage (FAC), and first MTP joints. Subjects were further categorized into 3 diagnostic groups: gout, asymptomatic hyperuricemia (no gout, serum uric acid [UA] ≥6.9 mg/dl), and controls (no gout, serum UA ≤6.8 mg/dl), and reader concordance within these 3 groups was assessed.Results: We observed almost perfect agreement between readers for 1) individual subjects (yes/no; n = 50, 100% agreement, κ = 1.000), 2) total joints (n = 200, 99% agreement, κ = 0.942), 3) FAC (n = 100, 99% agreement, κ = 0.942), and 4) first MTP joints (n = 100, 99% agreement, κ = 0.942). Furthermore, findings by side (right/left) and diagnostic group (gout, asymptomatic hyperuricemia, control) showed substantial to almost perfect concordance for all measures. MSU deposition was seen most commonly in gout patients, and deposition was also seen in some subjects with asymptomatic hyperuricemia, but in only 1 control.Conclusion: Musculoskeletal US is reliable for detecting MSU deposition in FAC and first MTP joints in gout and asymptomatic hyperuricemia.

1 May 2009 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
MSMyra G. Schneider
Myra G. Schneider
CSChristopher J. Swearingen
Christopher J. Swearingen
LSLisa M. Shulman
Lisa M. Shulman
JYJian Ye
Jian Ye
MBMona Baumgarten
Mona Baumgarten
BTBarbara C. Tilley
Barbara C. Tilley